Alphonse G Taghian

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5892078/publications.pdf

Version: 2024-02-01

36303 45317 9,026 174 51 90 citations h-index g-index papers 197 197 197 8345 docs citations citing authors all docs times ranked

#	Article	IF	CITATIONS
1	Diagnostic Criteria for Breast Cancer-Related Lymphedema of the Upper Extremity: The Need for Universal Agreement. Annals of Surgical Oncology, 2022, 29, 989-1002.	1.5	17
2	Risk of Developing Breast Reconstruction Complications: A Machine-Learning Nomogram for Individualized Risk Estimation with and without Postmastectomy Radiation Therapy. Plastic and Reconstructive Surgery, 2022, 149, 1e-12e.	1.4	15
3	A multiâ€institutional prediction model to estimate the risk of recurrence and mortality after mastectomy for <scp>T1â€2N1</scp> breast cancer. Cancer, 2022, 128, 3057-3066.	4.1	7
4	Radiation Modality (Proton/Photon), Timing, and Complication Rates in Patients With Breast Cancer Receiving 2-Stages Expander/Implant Reconstruction. Practical Radiation Oncology, 2022, 12, 475-486.	2.1	8
5	Standardization of lower extremity quantitative lymphedema measurements and associated patient-reported outcomes in gynecologic cancers. Gynecologic Oncology, 2021, 160, 625-632.	1.4	12
6	Use of technology to facilitate a prospective surveillance program for breast cancer-related lymphedema at the Massachusetts General Hospital. MHealth, 2021, 7, 11-11.	1.6	5
7	Letter to editor re: Shah et al.: "The impact of monitoring techniques on progression to chronic breast cancer-related lymphedema: a meta-analysis comparing bioimpedance spectroscopy versus circumferential measurements― Breast Cancer Research and Treatment, 2021, 186, 271-272.	2.5	1
8	ASO Author Reflections: The Promising Potential of Early Intervention for Subclinical Lymphedema in Women Who Underwent Nodal Surgery for Breast Cancer. Annals of Surgical Oncology, 2021, 28, 8634-8635.	1.5	1
9	ASO Visual Abstract: Subclinical Lymphedema After Treatment for Breast Cancer: Risk of Progression and Considerations for Early Intervention. Annals of Surgical Oncology, 2021, 28, 448.	1.5	2
10	Subclinical Lymphedema After Treatment for Breast Cancer: Risk of Progression and Considerations for Early Intervention. Annals of Surgical Oncology, 2021, 28, 8624-8633.	1.5	19
11	Regional Lymph Nodes Radiation and Breast Cancer Related Lymphedema: Where We Stand. International Journal of Radiation Oncology Biology Physics, 2021, 110, 1159-1160.	0.8	0
12	Weight loss does not decrease risk of breast cancer–related arm lymphedema. Cancer, 2021, 127, 3939-3945.	4.1	6
13	Locally Recurrent Secretory Carcinoma of the Breast with <i>NTRK3</i> Cene Fusion. Oncologist, 2021, 26, 818-824.	3.7	8
14	ASO Author Reflections: Breast Cancer-Related Lymphedemaâ€"A Suggested Clinical Pathway for Diagnosis. Annals of Surgical Oncology, 2021, , 1.	1.5	1
15	A Phase 1 Dose-Escalation Trial of Radiation Therapy and Concurrent Cisplatin for Stage II and III Triple-Negative Breast Cancer. International Journal of Radiation Oncology Biology Physics, 2021, 111, 45-52.	0.8	5
16	ASO Visual Abstract: Diagnostic Criteria for Breast Cancer-Related LymphedemaÂof the Upper Extremity—The Need for Universal Agreement. Annals of Surgical Oncology, 2021, 28, 680-681.	1.5	1
17	The important role of nighttime compression in breast cancer–related lymphedema treatment. Cancer, 2021, , .	4.1	1
18	Single Stage Direct-to-Implant Breast Reconstruction Has Lower Complication Rates Than Tissue Expander and Implant and Comparable Rates to Autologous Reconstruction in Patients Receiving Postmastectomy Radiation. International Journal of Radiation Oncology Biology Physics, 2020, 106, 514-524.	0.8	55

#	Article	IF	CITATIONS
19	Complications May Outweigh the Benefits. International Journal of Radiation Oncology Biology Physics, 2020, 108, 1131-1132.	0.8	0
20	In Reply to Kim etÂal. International Journal of Radiation Oncology Biology Physics, 2020, 107, 224.	0.8	1
21	Reply to: Bergmann et al comment to "Patients who report cording after breast cancer surgery are at higher risk of lymphedema: Results from a large prospective screening cohort― Journal of Surgical Oncology, 2020, 122, 999-1002.	1.7	0
22	Quantifying the Impact of Axillary Surgery and Nodal Irradiation on Breast Cancer–Related Lymphedema and Local Tumor Control: Long-Term Results From a Prospective Screening Trial. Journal of Clinical Oncology, 2020, 38, 3430-3438.	1.6	74
23	Breast Cancer-Related Lymphedema: a Review of Risk Factors, Radiation Therapy Contribution, and Management Strategies. Current Breast Cancer Reports, 2020, 12, 305-316.	1.0	4
24	Integrating Symptoms Into the Diagnostic Criteria for Breast Cancer–Related Lymphedema: Applying Results From a Prospective Surveillance Program. Physical Therapy, 2020, 100, 2186-2197.	2.4	13
25	Lymphoedema screening: setting the standard. British Journal of Cancer, 2020, 123, 1-2.	6.4	7
26	A review of the international early recommendations for departments organization and cancer management priorities during the global COVID-19 pandemic: applicability in low- and middle-income countries. European Journal of Cancer, 2020, 135, 130-146.	2.8	31
27	Patients who report cording after breast cancer surgery are at higher risk of lymphedema: Results from a large prospective screening cohort. Journal of Surgical Oncology, 2020, 122, 155-163.	1.7	11
28	Early Stage Node-Negative Postmastectomy Radiation Therapy—A Treatment Conundrum. International Journal of Radiation Oncology Biology Physics, 2020, , .	0.8	0
29	Optimal breast reconstruction type for patients treated with neoadjuvant chemotherapy, mastectomy followed by radiation therapy. Breast Cancer Research and Treatment, 2020, 183, 127-136.	2.5	16
30	Breast Cancer–Related Lymphedema: Risk Factors, Screening, Management, and the Impact of Locoregional Treatment. Journal of Clinical Oncology, 2020, 38, 2341-2350.	1.6	72
31	A retrospective analysis of commonly prescribed medications and the risk of developing breast cancer related lymphedema. Clinical Research and Trials, 2020, 6, .	0.1	7
32	Phase II Study of Proton Beam Radiation Therapy for Patients With Breast Cancer Requiring Regional Nodal Irradiation. Journal of Clinical Oncology, 2019, 37, 2778-2785.	1.6	64
33	Letter to Editor re: Ridner et al.: "A Randomized Trial Evaluating Bioimpedance Spectroscopy Versus Tape Measurement for the Prevention of Lymphedema Following Treatment for Breast Cancer: Interim Analysis― Annals of Surgical Oncology, 2019, 26, 863-864.	1.5	4
34	The Impact of Chest Wall Boost on Reconstruction Complications and Local Control in Patients Treated for Breast Cancer. International Journal of Radiation Oncology Biology Physics, 2019, 105, 155-164.	0.8	35
35	Tattoo free setup for partial breast irradiation: A feasibility study. Journal of Applied Clinical Medical Physics, 2019, 20, 45-50.	1.9	35
36	Lymphedema After Breast Cancer Treatment. , 2019, , 97-126.		0

#	Article	IF	CITATIONS
37	Incidence of peripheral edema in patients receiving PI3K/mTOR/CDK4/6 inhibitors for metastatic breast cancer. Breast Cancer Research and Treatment, 2019, 175, 649-658.	2.5	5
38	Is Postoperative Breast Radiation Therapy Safe in Patients With Scleroderma?. International Journal of Radiation Oncology Biology Physics, 2019, 104, 10-11.	0.8	6
39	"Only as an Ultimate Solution!― International Journal of Radiation Oncology Biology Physics, 2019, 104, 13-15.	0.8	O
40	Pragmatic randomised clinical trial of proton versus photon therapy for patients with non-metastatic breast cancer: the Radiotherapy Comparative Effectiveness (RadComp) Consortium trial protocol. BMJ Open, 2019, 9, e025556.	1.9	60
41	Randomized trials in accelerated partial breast irradiation: "Two wrongs don't make a right!!― Reports of Practical Oncology and Radiotherapy, 2019, 24, 695-696.	0.6	O
42	Timing of Lymphedema After Treatment for Breast Cancer: When Are Patients Most At Risk?. International Journal of Radiation Oncology Biology Physics, 2019, 103, 62-70.	0.8	107
43	Evaluation of radiation-induced cardiac toxicity in breast cancer patients treated with Trastuzumab-based chemotherapy. Breast Cancer Research and Treatment, 2019, 174, 179-185.	2.5	20
44	On "Diagnosis of Upper Quadrant Lymphedema Secondary to Cancer: Clinical Practice Guideline from the Oncology Section of the American Physical Therapy Association.―Levenhagen K, Davies C, Perdomo M, Ryans K, Gilchrist L. Phys Ther. 2017;97:729–745. Physical Therapy, 2018, 98, 277-281.	2.4	3
45	Machine learning to parse breast pathology reports in Chinese. Breast Cancer Research and Treatment, 2018, 169, 243-250.	2.5	22
46	Hand Edema in Patients at Risk of Breast Cancer–Related Lymphedema: Health Professionals Should Take Notice. Physical Therapy, 2018, 98, 510-517.	2.4	7
47	Letter to the editor of "Current and future perspectives on the evaluation, prevention and conservative management of breast cancer related lymphoedema: A best practice guideline―from N. Gebruers and colleagues. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2018, 225, 255-256.	1.1	1
48	Lymph node metastases can invade local blood vessels, exit the node, and colonize distant organs in mice. Science, 2018, 359, 1403-1407.	12.6	340
49	Breast cancer-related lymphedema: risk factors, precautionary measures, and treatments. Gland Surgery, 2018, 7, 379-403.	1.1	195
50	Effectiveness and tolerability of neoadjuvant pertuzumab-containing regimens for HER2-positive localized breast cancer. Breast Cancer Research and Treatment, 2018, 172, 733-740.	2.5	15
51	Perometry versus simulated circumferential tape measurement for the detection of breast cancer-related lymphedema. Breast Cancer Research and Treatment, 2018, 172, 83-91.	2.5	28
52	Predictors of surveillance mammography outcomes in women with a personal history of breast cancer. Breast Cancer Research and Treatment, 2018, 171, 209-215.	2.5	3
53	Adjuvant nodal radiotherapy in the era of sentinel node biopsy staging of breast cancer: A review of published guidelines and prospective trials and their implications on clinical practice. Critical Reviews in Oncology/Hematology, 2017, 112, 171-178.	4.4	6
54	Diagnostic Methods, Risk Factors, Prevention, and Management of Breast Cancer-Related Lymphedema: Past, Present, and Future Directions. Current Breast Cancer Reports, 2017, 9, 111-121.	1.0	60

#	Article	IF	CITATIONS
55	Postmastectomy radiation therapy technique and cardiopulmonary sparing: A dosimetric comparative analysis between photons and protons with free breathing versus deep inspiration breath hold. Practical Radiation Oncology, 2017, 7, e377-e384.	2.1	55
56	Using machine learning to parse breast pathology reports. Breast Cancer Research and Treatment, 2017, 161, 203-211.	2.5	87
57	Pathologic Complete Response After Neoadjuvant Chemotherapy and Long-Term Outcomes Among Young Women With Breast Cancer. Journal of the National Comprehensive Cancer Network: JNCCN, 2017, 15, 1216-1223.	4.9	88
58	Precautionary Behaviors and Breast Cancer-Related Lymphedema. Lymphatic Research and Biology, 2017, 15, 292-294.	1.1	2
59	Predictors of Disruptions in Breast Cancer Care for Individuals with Schizophrenia. Oncologist, 2017, 22, 1374-1382.	3.7	27
60	In response to: Letter to the Editor by Kilbreath et al Journal of Surgical Oncology, 2017, 115, 223-225.	1.7	1
61	Breast-cancer subtype, age, and lymph node status as predictors of local recurrence following breast-conserving therapy. Breast Cancer Research and Treatment, 2017, 161, 173-179.	2.5	77
62	Accelerated Partial Breast Irradiation: Executive summary for the update of an ASTRO Evidence-Based Consensus Statement. Practical Radiation Oncology, 2017, 7, 73-79.	2.1	483
63	Association Between Precautionary Behaviors and Breast Cancer–Related Lymphedema in Patients Undergoing Bilateral Surgery. Journal of Clinical Oncology, 2017, 35, 3934-3941.	1.6	51
64	Cost Implications of an Evidence-Based Approach to Radiation Treatment After Lumpectomy for Early-Stage Breast Cancer. Journal of Oncology Practice, 2017, 13, e283-e290.	2.5	24
65	Breast cancer care redesign as an approach to streamline survivorship care: Outcomes and challenges Journal of Clinical Oncology, 2017, 35, 9-9.	1.6	0
66	Establishing Cost-Effective Allocation of Proton Therapy for Breast Irradiation. International Journal of Radiation Oncology Biology Physics, 2016, 95, 11-18.	0.8	49
67	The need for preoperative baseline arm measurement to accurately quantify breast cancer-related lymphedema. Breast Cancer Research and Treatment, 2016, 157, 229-240.	2.5	60
68	Precautions for breast cancer-related lymphoedema: risk from air travel, ipsilateral arm blood pressure measurements, skin puncture, extreme temperatures, and cellulitis. Lancet Oncology, The, 2016, 17, e392-e405.	10.7	81
69	Case 30-2016. New England Journal of Medicine, 2016, 375, 1270-1281.	27.0	5
70	Left Ventricular Global Longitudinal Strain in HERâ€2 + Breast Cancer Patients Treated with Anthracyclines and Trastuzumab Who Develop Cardiotoxicity Is Associated with Subsequent Recovery of Left Ventricular Ejection Fraction. Echocardiography, 2016, 33, 519-526.	0.9	40
71	Reply to J. Nudelman. Journal of Clinical Oncology, 2016, 34, 3111-3112.	1.6	3
72	A comprehensive review of bioimpedance spectroscopy as a diagnostic tool for the detection and measurement of breast cancer-related lymphedema. Journal of Surgical Oncology, 2016, 114, 537-542.	1.7	55

#	Article	IF	Citations
73	Factors Associated with Recurrence Rates and Long-Term Survival in Women Diagnosed with Breast Cancer Ages 40 and Younger. Annals of Surgical Oncology, 2016, 23, 3212-3220.	1.5	26
74	Immediate Implant Reconstruction Is Associated With a Reduced Risk of Lymphedema Compared to Mastectomy Alone. Annals of Surgery, 2016, 263, 399-405.	4.2	33
75	Impact of Ipsilateral Blood Draws, Injections, Blood Pressure Measurements, and Air Travel on the Risk of Lymphedema for Patients Treated for Breast Cancer. Journal of Clinical Oncology, 2016, 34, 691-698.	1.6	136
76	Molecular Phenotype, Multigene Assays, and the Locoregional Management of Breast Cancer. Seminars in Radiation Oncology, 2016, 26, 9-16.	2.2	23
77	Effect of the micronutrient iodine in thyroid carcinoma angiogenesis. Aging, 2016, 8, 3180-3184.	3.1	8
78	Global Cancer Institute (GCI) multi-disciplinary tumor boards (MTBs) as an educational tool to improve guideline-based cancer clinical practice in low- and middle-income countries (LMICs) Journal of Clinical Oncology, 2016, 34, e18007-e18007.	1.6	0
79	Tolerability and effectiveness of pertuzumab-containing neoadjuvant (NA) regimens vs. AC-TH for HER2-positive (+) localized breast cancer (BC) Journal of Clinical Oncology, 2016, 34, 586-586.	1.6	0
80	Long-term outcomes among breast cancer patients with extensive regional lymph node involvement: implications for locoregional management. Breast Cancer Research and Treatment, 2015, 154, 633-639.	2.5	2
81	Establishing and Sustaining a Prospective Screening Program for Breast Cancer-Related Lymphedema at the Massachusetts General Hospital: Lessons Learned. Journal of Personalized Medicine, 2015, 5, 153-164.	2.5	50
82	Hypofractionated Whole Breast Irradiation for Early-Stage Breast Cancer. JAMA - Journal of the American Medical Association, 2015, 313, 1370.	7.4	1
83	In Reply to Lawrence. International Journal of Radiation Oncology Biology Physics, 2015, 93, 215-216.	0.8	1
84	Outcome Following Local-Regional Recurrence in Women with Early-Stage Breast Cancer: Impact of Biologic Subtype. Breast Journal, 2015, 21, 161-167.	1.0	27
85	Deep inspiration breath-hold technique in left-sided breast cancer radiation therapy: Evaluating cardiac contact distance as a predictor of cardiac exposure for patient selection. Practical Radiation Oncology, 2015, 5, e127-e134.	2.1	59
86	In Regard to Vaidya etÂal. International Journal of Radiation Oncology Biology Physics, 2015, 92, 952-953.	0.8	4
87	Radiation Therapy Risk Factors for Development of Lymphedema in Patients Treated With Regional Lymph Node Irradiation for Breast Cancer. International Journal of Radiation Oncology Biology Physics, 2015, 91, 760-764.	0.8	34
88	Impact of adjuvant taxane-based chemotherapy on development of breast cancer-related lymphedema: results from a large prospective cohort. Breast Cancer Research and Treatment, 2015, 151, 393-403.	2.5	75
89	The impact of breast cancer-related lymphedema on the ability to perform upper extremity activities of daily living. Breast Cancer Research and Treatment, 2015, 150, 381-388.	2.5	39
90	The Role of Sonographic Imaging to Assess the Pathophysiology of Cording in Patients Treated for Breast Cancer. Journal of Diagnostic Medical Sonography, 2015, 31, 276-281.	0.3	1

#	Article	IF	CITATIONS
91	Is a higher boost dose of radiation necessary after breast-conserving therapy for patients with breast cancer with final close or positive margins?. Breast Cancer Research and Treatment, 2015, 154, 71-79.	2.5	4
92	Nipple-Sparing Mastectomy in Irradiated Breasts: Selecting Patients to Minimize Complications. Annals of Surgical Oncology, 2015, 22, 3331-3337.	1.5	64
93	Breast cancer with extensive regional lymph node involvement: Toward optimizing local management Journal of Clinical Oncology, 2015, 33, 1053-1053.	1.6	1
94	Factors Associated With Fear of Lymphedema After Treatment for Breast Cancer. Oncology Nursing Forum, 2014, 41, 473-483.	1.2	20
95	Risk of lymphedema after mastectomy: potential benefit of applying ACOSOG Z0011 protocol to mastectomy patients. Breast Cancer Research and Treatment, 2014, 144, 71-77.	2.5	76
96	Is Biological Subtype Prognostic of Locoregional Recurrence Risk in Women With pT1-2N0 Breast Cancer Treated With Mastectomy?. International Journal of Radiation Oncology Biology Physics, 2014, 88, 57-64.	0.8	34
97	The Impact of Radiation Therapy on the Risk of Lymphedema After Treatment for Breast Cancer: A Prospective Cohort Study. International Journal of Radiation Oncology Biology Physics, 2014, 88, 565-571.	0.8	203
98	The impact of isolated tumor cells on loco-regional recurrence in breast cancer patients treated with breast-conserving treatment or mastectomy without post-mastectomy radiation therapy. Breast Cancer Research and Treatment, 2014, 146, 365-370.	2.5	10
99	Locoregional Recurrence and Survival Outcomes by Type of Local Therapy and Trastuzumab Use Among Women with Node-Negative, HER2-Positive Breast Cancer. Annals of Surgical Oncology, 2014, 21, 3490-3496.	1.5	15
100	Edmond-Philippe Malaise (1930-2013): A Lifetime of Perseverance Leads to the Cellular Definition of Intrinsic Radiosensitivity. International Journal of Radiation Oncology Biology Physics, 2014, 88, 1215-1217.	0.8	1
101	Clinical Outcome of Isolated Locoregional Recurrence in Patients With Breast Cancer According to Their Primary Local Treatment. Clinical Breast Cancer, 2014, 14, 198-204.	2.4	20
102	Long-term Cosmetic Outcomes and Toxicities of Proton Beam Therapy Compared With Photon-Based 3-Dimensional Conformal Accelerated Partial-Breast Irradiation: A Phase 1 Trial. International Journal of Radiation Oncology Biology Physics, 2014, 90, 493-500.	0.8	98
103	Blocking the formation of radiation-induced breast cancer stem cells. Oncotarget, 2014, 5, 3743-3755.	1.8	92
104	Fat necrosis of the breast in the accelerated partial breast irradiation era: the need for a universal grading system. Breast Cancer Research and Treatment, 2013, 140, 1-11.	2.5	20
105	Cording following treatment for breast cancer. Breast Cancer Research and Treatment, 2013, 140, 105-111.	2.5	48
106	Intensity modulated proton therapy for postmastectomy radiation of bilateral implant reconstructed breasts: A treatment planning study. Radiotherapy and Oncology, 2013, 107, 213-217.	0.6	72
107	Defining a threshold for intervention in breast cancer-related lymphedema: what level of arm volume increase predicts progression?. Breast Cancer Research and Treatment, 2013, 140, 485-494.	2.5	91
108	Residual Lymph Node Disease After Neoadjuvant Chemotherapy Predicts an Increased Risk of Lymphedema in Node-Positive Breast Cancer Patients. Annals of Surgical Oncology, 2013, 20, 2835-2841.	1.5	19

#	Article	IF	CITATIONS
109	Impact of body mass index and weight fluctuation on lymphedema risk in patients treated for breast cancer. Breast Cancer Research and Treatment, 2013, 142, 59-67.	2.5	90
110	Application of ACOSOG Z0011 Criteria Reduces Perioperative Costs. Annals of Surgical Oncology, 2013, 20, 836-841.	1.5	25
111	Lymphedema following treatment for breast cancer: A new approach to an old problem. Critical Reviews in Oncology/Hematology, 2013, 88, 437-446.	4.4	39
112	Localized Therapy for Male Breast Cancer: Functional Advantages With Comparable Outcomes Using Breast Conservation. Clinical Breast Cancer, 2013, 13, 344-349.	2.4	31
113	Proton Therapy for Breast Cancer After Mastectomy: Early Outcomes of a Prospective Clinical Trial. International Journal of Radiation Oncology Biology Physics, 2013, 86, 484-490.	0.8	144
114	Pathologic Response and Long-Term Follow-up in Breast Cancer Patients Treated With Neoadjuvant Chemotherapy: A Comparison Between Classifications and Their Practical Application. Archives of Pathology and Laboratory Medicine, 2013, 137, 1074-1082.	2.5	50
115	Screening for Breast Cancerâ€Related Lymphedema: The Need for Standardization. Oncologist, 2013, 18, 350-352.	3.7	22
116	In Reply. Oncologist, 2013, 18, 1243-1244.	3.7	1
117	Circulating Tumor Cells as Predictors of Response and Failure in Breast Cancer Patients Treated with Preoperative Chemotherapy. International Journal of Biological Markers, 2013, 28, 17-23.	1.8	6
118	Do locoregional recurrence and survival outcomes differ in women with node-negative, HER2-positive breast cancer treated with breast-conserving therapy versus mastectomy?. Journal of Clinical Oncology, 2013, 31, 69-69.	1.6	0
119	Predictors of Locoregional Recurrence After Neoadjuvant Chemotherapy: Results From Combined Analysis of National Surgical Adjuvant Breast and Bowel Project B-18 and B-27. Journal of Clinical Oncology, 2012, 30, 3960-3966.	1.6	473
120	Comparison of relative versus absolute arm size change as criteria for quantifying breast cancer-related lymphedema: the flaws in current studies and need for universal methodology. Breast Cancer Research and Treatment, 2012, 135, 145-152.	2.5	75
121	Sentinel lymph node biopsy at the time of mastectomy does not increase the risk of lymphedema: implications for prophylactic surgery. Breast Cancer Research and Treatment, 2012, 135, 781-789.	2.5	22
122	Brain metastases after breast-conserving therapy and systemic therapy: incidence and characteristics by biologic subtype. Breast Cancer Research and Treatment, 2012, 136, 153-160.	2.5	107
123	In Reply to Hannoun-Levi etÂal. International Journal of Radiation Oncology Biology Physics, 2012, 84, 306-307.	0.8	O
124	A Voluntary Breath-Hold Treatment Technique for the Left Breast With Unfavorable Cardiac Anatomy Using Surface Imaging. International Journal of Radiation Oncology Biology Physics, 2012, 84, e663-e668.	0.8	50
125	Cost Comparison of Radiation Treatment Options After Lumpectomy for Breast Cancer. Annals of Surgical Oncology, 2012, 19, 3275-3281.	1.5	54
126	Phase II trial of 3D-conformal accelerated partial breast irradiation: Lessons learned from patients and physicians' evaluation. Radiotherapy and Oncology, 2012, 103, 193-198.	0.6	9

#	Article	IF	Citations
127	Can Axillary Node Dissection Be Omitted in a Subset of Patients with Low Local and Regional Failure Rates?. Breast Journal, 2012, 18, 23-27.	1.0	7
128	Association of pathologic complete response following neoadjuvant chemotherapy with survival among young women with breast cancer Journal of Clinical Oncology, 2012, 30, 1122-1122.	1.6	38
129	Use of Tamoxifen With Postsurgical Irradiation May Improve Survival in Estrogen and Progesterone Receptor–Positive Male Breast Cancer. Clinical Breast Cancer, 2011, 11, 39-45.	2.4	48
130	Standardized Method for Quantification of Developing Lymphedema in Patients Treated for Breast Cancer. International Journal of Radiation Oncology Biology Physics, 2011, 79, 1436-1443.	0.8	121
131	Age, Breast Cancer Subtype Approximation, and Local Recurrence After Breast-Conserving Therapy. Journal of Clinical Oncology, 2011, 29, 3885-3891.	1.6	381
132	Three-field Electron/Minitangent Photon Technique Offer Dosimetric Advantages to a Multifield, Photon-only Technique for Accelerated Partial Breast Irradiation if Well Implemented. American Journal of Clinical Oncology: Cancer Clinical Trials, 2011, 34, 648.	1.3	3
133	A Mixed-Modality 3D-Conformal Accelerated Partial Breast Irradiation Technique Using Opposed Mini-Tangent Photon Fields and en Face Electrons to Minimize the Lung Exposure to Radiation: In Regard to Jain et al. (Int J Radiat Oncol Biol Phys 2009;75:82-88) International Journal of Radiation Oncology Biology Physics. 2010, 76, 956-957.	0.8	7
134	In Reply to Dr. Lawrence. International Journal of Radiation Oncology Biology Physics, 2010, 78, 638.	0.8	0
135	Validation of a Web-Based Predictive Nomogram for Ipsilateral Breast Tumor Recurrence After Breast Conserving Therapy. Journal of Clinical Oncology, 2010, 28, 718-722.	1.6	66
136	Accelerated partial breast irradiation using TARGIT: the pros, cons and the need for long-term results. Expert Review of Anticancer Therapy, 2010, 10, 1869-1875.	2.4	3
137	Lung Dose-Volume Parameters and the Risk of Pneumonitis for Patients Treated With Accelerated Partial-Breast Irradiation Using Three-Dimensional Conformal Radiotherapy. Journal of Clinical Oncology, 2009, 27, 3887-3893.	1.6	59
138	Utility of DNA Repair Protein Foci for the Detection of Putative BRCA1 Pathway Defects in Breast Cancer Biopsies. Molecular Cancer Research, 2009, 7, 1304-1309.	3.4	105
139	Breast Conservation Therapy for Patients With Locally Advanced Breast Cancer. Seminars in Radiation Oncology, 2009, 19, 229-235.	2.2	18
140	Rebuttal to Dr. Wazer. Brachytherapy, 2009, 8, 189.	0.5	1
141	Counterpoint: Conformal external beam for accelerated partial breast irradiation. Brachytherapy, 2009, 8, 184-188.	0.5	9
142	Outcome of multiple-wire localization for larger breast cancers: do multiple wires translate into additional imaging, biopsies, and recurrences?. American Journal of Surgery, 2009, 198, 368-372.	1.8	7
143	Post-mastectomy radiation in large node-negative breast tumors: Does size really matter?. Radiotherapy and Oncology, 2009, 91, 33-37.	0.6	19
144	Outcomes of Multiple Wire Localization for Larger Breast Cancers: When Can Mastectomy Be Avoided?. Journal of the American College of Surgeons, 2008, 207, 342-346.	0.5	30

#	Article	IF	CITATIONS
145	Lumpectomy and partial breast irradiation for early-stage breast cancer following mantle irradiation for Hodgkin's lymphoma. Nature Clinical Practice Oncology, 2008, 5, 426-429.	4.3	16
146	Nomogram for the Prediction of Having Four or More Involved Nodes for Sentinel Lymph Node–Positive Breast Cancer. Journal of Clinical Oncology, 2008, 26, 2093-2098.	1.6	129
147	Breast Cancer Subtype Approximated by Estrogen Receptor, Progesterone Receptor, and HER-2 Is Associated With Local and Distant Recurrence After Breast-Conserving Therapy. Journal of Clinical Oncology, 2008, 26, 2373-2378.	1.6	745
148	Is It Time to Use Protons for Breast Cancer?. Cancer Journal (Sudbury, Mass), 2007, 13, 84-86.	2.0	5
149	Microscopic anatomy within the nipple: implications for nipple-sparing mastectomy. American Journal of Surgery, 2007, 194, 433-437.	1.8	62
150	Partialâ€"breast irradiation: towards a replacement for wholeâ€"breast irradiation?. Expert Review of Anticancer Therapy, 2007, 7, 123-134.	2.4	7
151	Management and Outcome of Ipsilateral Recurrence Following Breast Conservation. Seminars in Breast Disease, 2007, 10, 169-177.	0.0	0
152	Radiotherapy in Setting of Collagen Vascular Disease. International Journal of Radiation Oncology Biology Physics, 2007, 69, 1347-1353.	0.8	35
153	Initial dosimetric experience using simple three-dimensional conformal external-beam accelerated partial-breast irradiation. International Journal of Radiation Oncology Biology Physics, 2006, 64, 1092-1099.	0.8	91
154	Accelerated partial breast irradiation using proton beams: Initial dosimetric experience. International Journal of Radiation Oncology Biology Physics, 2006, 65, 1404-1410.	0.8	72
155	Topotecan Can Compensate for Protracted Radiation Treatment Time Effects in High Grade Glioma Xenografts*. Journal of Neuro-Oncology, 2006, 76, 31-38.	2.9	12
156	Update on accelerated partial-breast irradiation. Current Oncology Reports, 2006, 8, 35-41.	4.0	5
157	Low Locoregional Recurrence Rate Among Node-Negative Breast Cancer Patients With Tumors 5 cm or Larger Treated by Mastectomy, With or Without Adjuvant Systemic Therapy and Without Radiotherapy: Results From Five National Surgical Adjuvant Breast and Bowel Project Randomized Clinical Trials. Journal of Clinical Oncology, 2006, 24, 3927-3932.	1.6	103
158	Current Perceptions Regarding Surgical Margin Status After Breast-Conserving Therapy. Annals of Surgery, 2005, 241, 629-639.	4.2	194
159	Is a reduction in radiation lung volume and dose necessary with paclitaxel chemotherapy for node-positive breast cancer?. International Journal of Radiation Oncology Biology Physics, 2005, 62, 386-391.	0.8	20
160	Tubular Carcinoma of the Breast: a Retrospective Analysis and Review of the Literature. Breast Cancer Research and Treatment, 2005, 93, 199-205.	2.5	61
161	Prospective Comparison of Mammography, Sonography, and MRI in Patients Undergoing Neoadjuvant Chemotherapy for Palpable Breast Cancer. American Journal of Roentgenology, 2005, 184, 868-877.	2.2	349
162	Paclitaxel Decreases the Interstitial Fluid Pressure and Improves Oxygenation in Breast Cancers in Patients Treated With Neoadjuvant Chemotherapy: Clinical Implications. Journal of Clinical Oncology, 2005, 23, 1951-1961.	1.6	180

#	ARTICLE	IF	CITATIONS
163	Patterns of Locoregional Failure in Patients With Operable Breast Cancer Treated by Mastectomy and Adjuvant Chemotherapy With or Without Tamoxifen and Without Radiotherapy: Results From Five National Surgical Adjuvant Breast and Bowel Project Randomized Clinical Trials. Journal of Clinical Oncology, 2004, 22, 4247-4254.	1.6	348
164	The Effect of Delaying Radiation Therapy for Systemic Chemotherapy on Local-regional Control in Breast Cancer. Breast Cancer Research and Treatment, 2004, 84, 161-171.	2.5	13
165	The management of ductal carcinoma in situ in North America and Europe. Cancer, 2004, 101, 1958-1967.	4.1	48
166	Results of a survey regarding irradiation of internal mammary chain in patients with breast cancer: Practice is culture driven rather than evidence based. International Journal of Radiation Oncology Biology Physics, 2004, 60, 706-714.	0.8	63
167	In vitro and in vivo radiation sensitivity of glioblastoma multiforme: Correction. International Journal of Radiation Oncology Biology Physics, 2001, 49, 291.	0.8	0
168	Predictive value of histologic tumor necrosis after radiation. International Journal of Cancer, 2001, 96, 334-340.	5.1	3
169	Animal Systems for Translational Research in Radiation Oncology. Acta Oncológica, 1999, 38, 829-838.	1.8	18
170	THE ROLE OF RADIATION THERAPY FOR PRIMARY BREAST CANCER. Surgical Clinics of North America, 1999, 79, 1091-1115.	1.5	23
171	Repopulation capacity during fractionated irradiation of squamous cell carcinomas and glioblastomas in vitro. International Journal of Radiation Oncology Biology Physics, 1997, 39, 743-750.	0.8	53
172	Comparison between the in vitro intrinsic radiation sensitivity of human soft tissue sarcoma and breast cancer cell lines., 1996, 61, 290-294.		28
173	Growth and metastatic behavior of five human glioblastomas compared with nine other histological types of human tumor xenografts in SCID mice. Journal of Neurosurgery, 1995, 83, 308-315.	1.6	69
174	Clinical implications of heterogeneity of tumor response to radiation therapy. Radiotherapy and Oncology, 1992, 25, 251-260.	0.6	140